SEC Form 4 · accession 0001619008-15-000001
Diplomat Pharmacy, Inc. · DPLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atheer A Kaddis
Officer — SVP of Sales & Business Dev · Director
Period of report
Sep 8, 2015
Accepted (ET)
Sep 8, 2015 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610092
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 8, 2015 | M | 12,325 | $3.07 | A | 12,325 | D | |
| Common StockF1,F2 | Sep 8, 2015 | S | 12,325 | $37.416 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option to Acquire Common StockF3 | $3.07 | Sep 8, 2015 | M | 12,325 | D | — | Apr 1, 2019 | Common Stock | 12,325 | 431,375 | D |
Explanation of responses
- F1The sale was effected pursuant to a 10b-5-1 trading plan initially adopted by the reporting person on August 6, 2015. The plan provides for monthly sales of 12,325 shares of common stock at the market price. Shares that are not sold in a particular month will be available for sale in subsequent months under the plan. A maximum of 135,575 shares remain available for sale under the plan, which is set to expire on August 31, 2016.
- F2The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $37.26 to $37.63 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.
- F3The options were granted on April 1, 2009. The options began to vest in annual increments of 25% of the option grant on the one-year anniversary of the grant date, to be fully vested after four years. 100% of the options originally granted are currently vested and exercisable.